Stock vs Stock Comparison

Apellis Pharmaceuticals, Inc. vs Johnson & Johnson

JNJ wins the Tale of the Tape 7–2.

APLS
JNJ$222.89

🏆 Tale of the Tape

27
APLSJNJ
2.2%Profitability (Net Margin)28.5%
224.4xValuation (P/E)26.1x
7.2%Efficiency (ROIC)18.3%
7/9Health (Piotroski F)4/9
2.4Safety (Altman Z)4.0
28.5%Growth (Rev YoY)6.0%
Risk (Sharpe 1Y)2.69
1.90xBalance Sheet (D/E)1.44x
0.89%FCF Yield3.25%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Fundamentals

MetricAPLSJNJ
Market Cap$5.2B$542.4B
P/E Ratio224.4x26.1x
Forward P/E-131.1x17.7x
P/B13.82x6.68x
Dividend Yield2.38%
Beta0.290.26

Quantitative Metrics

MetricAPLSJNJ
DCF Fair Value$9.27$134.24
DCF Upside-43.6%
Piotroski F7/94/9
Altman Z2.393.97
Beneish M-2.45-2.27
FCF Yield0.89%3.25%
Net Debt/EBITDA-1.5x0.5x
ROIC7.2%18.3%
WACC7.7%7.7%
ROIC – WACC-0.5pp10.5pp
Gross Margin89.8%67.9%
Net Margin2.2%28.5%
Rev Growth YoY28.5%6.0%
Sharpe (1Y)2.69
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%

APLS Price

Loading chart...

JNJ Price

Loading chart...

ETF Exposure

APLS found in:

VBK0.13%
VHT0.05%
VONG0.01%

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

APLS vs JNJ: Head-to-Head Analysis

Apellis Pharmaceuticals, Inc. (APLS) and Johnson & Johnson (JNJ) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 7–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, APLS generates a return on invested capital (ROIC) of 7.2% compared to JNJ's 18.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

APLS appears in 3 ETFs tracked by SecuritiesDB, while JNJ appears in 39 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, APLS or JNJ?

Our quantitative analysis compares APLS and JNJ across nine fundamental dimensions. JNJ wins the Tale of the Tape 7–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are APLS and JNJ correlated?

Correlation data is not yet available for this pair. Check back after both stocks have sufficient trading history.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.